AviadoBio has significantly broadened its strategic horizons through an expanded exclusive licensing agreement with King’s College London. This pivotal development…
Read More
SpliSense Advances Promising Cystic Fibrosis Therapy with Significant Funding and Phase IIb Trial Launch
The biotech firm SpliSense is making significant strides in the development of a novel therapy for cystic fibrosis, announcing a…
Read More
EHA26: J&J’s multiple myeloma therapies impress with new data – Pharmaceutical Technology
The European Hematology Association (EHA) 2026 conference, held from June 11th to 14th in Stockholm, Sweden, served as a pivotal…
Read More
Salesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
In a significant move underscoring the escalating competition in the life sciences technology sector, Salesforce announced that over 140 life…
Read More
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…
Read More
Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis
Simcere Pharmaceutical Group has forged a significant research collaboration with Stanford Medicine, aiming to unlock novel therapeutic avenues for idiopathic…
Read More
FDA Approves a Wave of Oncology Innovations: New Therapies, Diagnostics, and Imaging Agents Usher in a New Era of Cancer Care
The US Food and Drug Administration (FDA) has recently authorized a series of significant advancements in oncology, encompassing novel therapeutic…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
Across the global pharmaceutical landscape, a staggering number of potentially life-changing therapies for rare diseases lie dormant, gathering dust on…
Read More
UK Approves Lower Dose of Needle-Free Adrenaline Nasal Spray for Young Children
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for a new, lower dose of ALK-Abelló’s…
Read More
Akeso Secures NMPA Approval for Gumokimab to Treat Plaque Psoriasis in China
Akeso has announced a significant milestone in its therapeutic pipeline with the National Medical Products Administration (NMPA) of China granting…
Read MoreYOU MAY HAVE MISSED
